受全球新冠疫情影响，原定于5月29日~6月2日在芝加哥举行的美国临床肿瘤学会（ASCO）年会今年将首次以线上形式举办，这是目前最大规模的线上盛会。今天，会议的摘要题目公布，共103个sessions，中国共有11项研究入选口头报告，17项入选Poster
Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.
Session: Breast Cancer—Metastatic
Author(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou
吡咯替尼或拉帕替尼加卡培他滨用于HER2+转移性乳腺癌（PHOEBE）：一项III期随机试验。
专场：转移性乳腺癌
作者：中国医学科学院肿瘤医院徐兵河教授、马飞教授，复旦大学附属肿瘤医院胡夕春教授等
摘要号：1003
Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).
Session: Breast Cancer—Local/Regional/Adjuvant
Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan
Abstract: 507
可手术三阴性乳腺癌标准治疗后卡培他滨维持节拍化疗的III期试验（SYSUCC-001）。
专场：乳腺癌—局部/区域/辅助治疗
作者：中山大学肿瘤防治中心王树森教授等
摘要号：507
Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.
Session: New Tools to Combat Old Foes
Author(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun Chen
利用转移性脑肿瘤的表型特征来预测脑脊液中循环肿瘤DNA检测的概率: 新工具对抗老对手
专场：新工具解决老问题
作者：李美芹 李德兰等
摘要号: 2507
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen
Abstract: 4506
多纳非尼对比索拉非尼作为晚期肝细胞癌的一线治疗：一项开放标签、随机、多中心II/III期试验。
专场：胃肠道癌—胃食管、胰腺和肝胆
作者：四川大学华西医院毕锋教授、中国人民解放军八一医院秦叔逵教授等
摘要号：4506
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin
Abstract: 4507
中国晚期肝癌患者阿帕替尼二线治疗：一项随机、安慰剂对照、双盲III期研究
专场：胃肠道癌—胃食管、胰腺和肝胆
作者：中国人民解放军八一医院秦叔逵教授、四川大学华西医院李秋教授等
摘要号：4507
A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.
Session: Gynecologic Cancer
Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai
Abstract: 6001
晚期复发性卵巢癌二次肿瘤细胞减灭术的一项随机III期试验：SOC1 / SGOG-OV2。
专题：妇科癌症
作者：复旦大学附属中山医院臧荣余教授等
摘要：6001
Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.
Session: Gynecologic Cancer
Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu
Abstract: 6007
IB1-IIA2期宫颈癌根治性子宫切除术后辅助治疗中的序贯放化疗对比单独放疗或同步放化疗（STARS研究）：一项随机、对照、开放标签的III期试验。
会议：妇科癌症
作者：中山大学肿瘤防治中心黄鹤教授、刘继红教授等
摘要号：6007
CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou
Abstract: 9005
CTONG1104：辅助吉非替尼对比化疗用于可切除的EGFR突变的N1-N2期NSCLC-随机III期临床试验的最终总体生存分析。
专题：肺癌—非小细胞局部-区域/小细胞/其他胸部肿瘤
作者：广东省人民医院吴一龙教授等
摘要号：9005
First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).
Session: Lung Cancer—Non-Small Cell Metastatic
Author(s): Xiaoshan Wang, Ming Zeng
Abstract: 9508
EGFR突变寡转移非小细胞肺癌患者一线酪氨酸激酶抑制剂联合或不联合积极前线局部放疗：III期开放标签临床随机试验（SINDAS）的中期结果（NCT02893332）。
专题：肺癌-非小细胞转移
作者：四川省人民医院曾铭教授等
摘要：9508
Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.
Session: Melanoma/Skin Cancers
Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo
Abstract: 10007
Toripalimab，一种针对程序性死亡-1（PD-1）的人源化IgG4单克隆抗体联合阿昔替尼用于转移性黏膜黑色素瘤患者的Ib期研究的总生存期和生物标志物分析。
专题：黑色素瘤/皮肤癌
作者：北京大学肿瘤医院郭军、盛锡楠教授等
摘要：10007
Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).
Session: Developmental Therapeutics—Immunotherapy
Author(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi Zhang
Abstract: 3013
Poster: 77
GC027的安全性和疗效结果：通用CAR-T细胞首次人体试验治疗成人复发/难治性T细胞急性淋巴细胞白血病（r/r T-ALL）的安全性和疗效。
会议：开发中的治疗技术-免疫治疗。
作者：王欣欣等
摘要：3013
海报：77
Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).
Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi Wang
Abstract: 4511
Poster: 119
信迪利单抗在晚期食管鳞状细胞癌患者中的应用：一项随机的开放标签II期试验（ORIENT-2）。
会议：胃肠道癌-胃食管癌、胰腺癌和肝胆道癌
作者：徐建明教授等
摘要：4511
海报：119
Eradication of medulloblastoma by NKG2D-specific CAR T-cells.
Session: Central Nervous System Tumors
Author(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong Zhao
Abstract: 2522
Poster: 13
NKG2D特异性CAR-T细胞对髓母细胞瘤的根除性治疗
会议：中枢神经系统肿瘤
作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东
摘要：2522
海报。13
Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.
Session: Developmental Therapeutics—Immunotherapy
Author(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, David Liu
Abstract: 3021
Poster: 85
Envafolimab（KN035）在晚期肿瘤错配修复缺陷患者中的应用
会议：开发中的治疗学-免疫治疗
作者：沈琳教授等
摘要：3021
海报。85
First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.
Session: Developmental Therapeutics—Immunotherapy
Author(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen Zhang
Abstract: 3026
Poster: 90
自体CD7-CART治疗复发/难治性ACUTE淋巴细胞白血病/淋巴瘤的首例人体临床试验
会议: 开发性治疗学-免疫治疗
作者简介：张明志，杨林等
摘要：3026
海报: 90
A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Author(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin Shen
Abstract: 3523
Poster: 253
西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合应用于晚期实体瘤患者的Ib期研究
会议：发展性治疗学--分子靶向药物和肿瘤生物学
作者：龚继芳，沈琳教授等
摘要：3523
海报：253
A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong Tan
Abstract: 4522
Poster: 130
Rh-endostatin联合紫杉醇和nedaplatin治疗复发性或转移性食管鳞状细胞癌（ESCC）患者的II期研究。
会议：胃肠道癌-胃食管、胰腺和肝胆道癌的研究
作者：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼
摘要：4522
海报：130
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.
Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Author(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing Huang
Abstract: 4524
Poster: 132
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.
会议：胃肠道癌-胃食管癌、胰腺癌和肝胆管癌的二线治疗
作者：宋艳等
摘要：4524
海报：132
A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.
Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Author(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao Zhang
Abstract: 5522
Poster: 103
一种尿液外体环状RNA分类器用于初始活检时检测高等级前列腺癌的尿液外体环状RNA分类器：一项多中心的回顾性研究
会议：泌尿生殖系统癌症---前列腺癌、睾丸癌和阴茎癌
作者简介：Liaoyuan Li等
摘要：5522
海报。103
Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.
Session: Gynecologic Cancer
Author(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin Li
Abstract: 6031
Poster: 202
局部晚期宫颈癌并发化疗后的辅助化疗
会议: 妇科癌症
作者简介： 李珉珉等
摘要：6031
海报：202
Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An analysis based on the ALTER01031 trial.
Session: Head and Neck Cancer
Author(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng
Abstract: 6526
Poster: 187
降钙素与安罗替尼治疗甲状腺髓性癌的疗效相关性：基于ALTER01031试验的分析。
会话：头颈部肿瘤
作者：天津市肿瘤医院高明教授
摘要：6526
海报。187
Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup analysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).
Session: Head and Neck Cancer
Author(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng
Abstract: 6527
Poster: 188
ECOG PS、肿瘤大小和年龄对安洛替尼治疗后患者结局的影响: ALTER01031的亚组分析
会议：头颈部肿瘤
作者：天津市肿瘤医院高明教授
摘要：6527
海报。188
Circulating tumor DNA (ctDNA) analysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.
Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Author(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi Wu
Abstract: 9023
Poster: 216
ctDNA分析预测I-IIIA期非小细胞肺癌（NSCLC）患者术后复发: GASTO1035和GASTO1018的结果
会议：肺癌-非小细胞局部-区域性/小细胞/小细胞/其他胸科癌症
作者：Si-Yu Wang等
摘要：9023
海报：216
Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).
Session: Lung Cancer—Non-Small Cell Metastatic
Author(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min Fan
Abstract: 9528
Poster: 294
ERBB2ΔEx16作为非小细胞肺癌（NSCLC）中EGFR酪氨酸激酶抑制剂的新型耐药机制
会议:肺癌-非小细胞转移性肺癌
作者简介：赵昕，金玲玲，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧秋香、华宝、薛武、杨绍、范敏
摘要：9528
海报：294
Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
Session: Melanoma/Skin Cancers
Author(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei Zhou
Abstract: 10030
Poster: 379
PD-1/PD-L1试验中晚期黑色素瘤总生存的替代终点
会议：黑色素瘤/皮肤癌
作者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟
摘要：10030
海报：379
A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.
Session: Sarcoma
Author(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang Yao
Abstract: 11525
Poster: 413
安罗替尼治疗复发或转移性原发性恶性骨肿瘤患者的II期研究
会议： 肉瘤
作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶
摘要：11525
海报。413
Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.
Session: Sarcoma
Author(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying Niu
Abstract: 11526
Poster: 414
初步评价安罗替尼在晚期肉瘤患者多线治疗中的安全性和疗效。
会议：肉瘤
作者：姚伟涛，王家强，张鹏，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王家强、张鹏、王鑫、杜鑫辉、田志超、牛晓英
摘要：11526
海报：414
来源：MedSci原创
版权声明：
本网站所有注明“来源：梅斯医学”或“来源：MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有，非经授权，任何媒体、网站或个人不得转载，授权转载时须注明“来源：梅斯医学”。本网所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。同时转载内容不代表本站立场。
在此留言
